ArticleAbdominal radiology (New York)2026
Transarterial chemoembolization with prophylactic right inferior phrenic artery embolization for hepatocellular carcinoma in segments VII and VIII.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis retrospective study aimed to compare the efficacy and safety of conventional lipiodol-based transarterial chemoembolization (TACE) combined with prophylactic right inferior phrenic artery (RIPA) embolization versus TACE alone for hepatocellular carcinoma (HCC) located in liver segments VII and VIII.
methodsAfter propensity score matching of 161 eligible patients, 52 received TACE alone (Group A) and 52 received TACE plus prophylactic RIPA embolization (Group B). Primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), time to progression (TTP), tumor response, and adverse events (AEs).
resultsThe combination therapy significantly improved survival outcomes. Median OS was 32.3 vs. 28.3 months, median PFS was 18.8 vs. 16.5 months, and median TTP was 19.3 vs. 17.5 months. Multivariable Cox analysis confirmed prophylactic RIPA embolization as an independent favorable prognostic factor for OS (HR 0.511, P=0.008), PFS (HR 0.528, P=0.003), and TTP (HR 0.502, P=0.002). Other independent factors included tumor number >3 and Child-Pugh class. The 1-month objective response rate showed no significant difference (67.3% vs. 55.8%, P=0.277). Regarding safety, the overall AE rate was similar between groups (44.2% vs. 42.3%). Complications specifically associated with RIPA embolization in Group B included shoulder pain (19.2%) and hiccups (13.5%), which were mild and self-limited. The incidence of major complications (SIR class C-F) was not significantly different (7.7% vs. 3.8%, P=0.678). One patient in Group B developed a grade 4 liver abscess.
conclusionsFor HCC in segments VII/VIII, adding prophylactic RIPA embolization to conventional lipiodol-based TACE provides significant survival benefits, establishing it as an independent prognostic factor, without substantially increasing major treatment-related morbidity. This combined approach represents a valuable therapeutic strategy for this specific patient subset.
Indexed as
Identifiers
41801381What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.